
NASDAQHealthcareMedical - Instruments & Supplies
Latest quote
$4.47
−$0.05 · -1.11%
Nephros, Inc. is a company that specializes in developing and marketing sophisticated water purification solutions across the United States, catering to both the medical and commercial sectors. Its operations are structured into three primary segments: Water Filtration, Pathogen Detection, and Renal Products. Within its Water Filtration division, Nephros offers advanced ultrafiltration products. These are vital in dialysis centers for eradicating biological contaminants from water and bicarbonate concentrate, and are also deployed in hospitals to prevent infections from waterborne pathogens such as Legionella and Pseudomonas. Their utility extends to military installations, outdoor recreation, commercial establishments, and various other healthcare facilities. The Pathogen Detection segment focuses on developing and distributing real-time water testing systems, which deliver critical, actionable data regarding waterborne pathogens. Furthermore, under its Renal Products segment, the company provides medical devices designed for individuals suffering from renal disease, notably including a second-generation hemodiafiltration system tailored for patients with end-stage renal disease. Additionally, Nephros markets a range of water filters under the Nephros and AETHER brands. These filters are engineered not only to enhance water taste and eliminate odors but also to significantly reduce biofilm, bacteria, and scale accumulation in downstream equipment, serving the food service, hospitality, convenience store, and healthcare industries. Established in 1997, Nephros, Inc. maintains its corporate headquarters in South Orange, New Jersey.
Previous close
$4.47
−$0.05 · -1.11%
Regular session · ET · Market data may be delayed.
Nephros, Inc. is a company that specializes in developing and marketing sophisticated water purification solutions across the United States, catering to both the medical and commercial sectors. Its operations are structured into three primary segments: Water Filtration, Pathogen Detection, and Renal Products. Within its Water Filtration division, Nephros offers advanced ultrafiltration products. These are vital in dialysis centers for eradicating biological contaminants from water and bicarbonate concentrate, and are also deployed in hospitals to prevent infections from waterborne pathogens such as Legionella and Pseudomonas. Their utility extends to military installations, outdoor recreation, commercial establishments, and various other healthcare facilities. The Pathogen Detection segment focuses on developing and distributing real-time water testing systems, which deliver critical, actionable data regarding waterborne pathogens. Furthermore, under its Renal Products segment, the company provides medical devices designed for individuals suffering from renal disease, notably including a second-generation hemodiafiltration system tailored for patients with end-stage renal disease. Additionally, Nephros markets a range of water filters under the Nephros and AETHER brands. These filters are engineered not only to enhance water taste and eliminate odors but also to significantly reduce biofilm, bacteria, and scale accumulation in downstream equipment, serving the food service, hospitality, convenience store, and healthcare industries. Established in 1997, Nephros, Inc. maintains its corporate headquarters in South Orange, New Jersey.
Day range
Current $4.47
52-week range
Current $4.47
Regular session · ET · Market data may be delayed.
GoAI Score
Hold
Valuation
76
Undervalued
Sentiment
68
Bullish
Risk
76
High Risk
Momentum
36
Weakening
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Nephros, Inc. is a company that specializes in developing and marketing sophisticated water purification solutions across the United States, catering to both the medical and commercial sectors. Its operations are structured into three primary segments: Water Filtration, Pathogen Detection, and Renal Products. Within its Water Filtration division, Nephros offers advanced ultrafiltration products. These are vital in dialysis centers for eradicating biological contaminants from water and bicarbonate concentrate, and are also deployed in hospitals to prevent infections from waterborne pathogens such as Legionella and Pseudomonas. Their utility extends to military installations, outdoor recreation, commercial establishments, and various other healthcare facilities. The Pathogen Detection segment focuses on developing and distributing real-time water testing systems, which deliver critical, actionable data regarding waterborne pathogens. Furthermore, under its Renal Products segment, the company provides medical devices designed for individuals suffering from renal disease, notably including a second-generation hemodiafiltration system tailored for patients with end-stage renal disease. Additionally, Nephros markets a range of water filters under the Nephros and AETHER brands. These filters are engineered not only to enhance water taste and eliminate odors but also to significantly reduce biofilm, bacteria, and scale accumulation in downstream equipment, serving the food service, hospitality, convenience store, and healthcare industries. Established in 1997, Nephros, Inc. maintains its corporate headquarters in South Orange, New Jersey.
Day range
Current $4.47
52-week range
Current $4.47
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 18.79M USD | 14.16M USD | 14.24M USD | 9.98M USD | 10.22M USD |
| Cost of goods sold | 7.3M USD | 5.44M USD | 5.83M USD | 5.24M USD | 4.58M USD |
| Gross profit | 11.49M USD | 8.72M USD | 8.41M USD | 4.73M USD | 5.63M USD |
| Research and development | 1.34M USD | 906K USD | 873K USD | 1.26M USD | 1.5M USD |
| Selling, general, and administrative | 9M USD | 7.68M USD | 8.91M USD | 7.59M USD | 7.2M USD |
| Operating expenses | 10.34M USD | 8.72M USD | 10M USD | 9.07M USD | 8.89M USD |
| Interest income | 139K USD | 94K USD | 64K USD | 14K USD | 10K USD |
| Interest expense | 1K USD | 1K USD | 2K USD | 20K USD | 41K USD |
| Depreciation and amortization | 140K USD | 137K USD | 214K USD | 571K USD | 252K USD |
| Operating income | 1.15M USD | 6K USD | −1.59M USD | −4.34M USD | −3.25M USD |
| Net income | 1.19M USD | 74K USD | −1.58M USD | −7.38M USD | −4.11M USD |
Company facts updated Sep 12, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Limited analyst sample: 4 ratings. Interpret the distribution with caution.
Funds reporting this stock among their holdings, ordered by reported position size.
Vanguard Morningstar Total Stock Market ETFVTI443.75K0.00%2.3T USD0.03%$376.31+0.82%
Vanguard Extended Market ETFVXF229.65K0.00%93.7B USD0.05%$237.76+0.68%
iShares Micro-Cap ETFIWC79.67K0.01%1.44B USD0.60%$190.84+0.39%
Dimensional - US Core Equity 2 ETFDFAC21.75K0.00%49.17B USD0.17%$45.16+0.71%
Dimensional - US Core Equity 1 ETFDCOR11.13K0.00%3.58B USD0.14%$83.91+0.75%
Dimensional - US Sustainability Core 1 ETFDFSU1.85K0.00%2.35B USD0.15%$47.79+0.82%
Vanguard Morningstar Total Stock Market ETFVTI
Vanguard Extended Market ETFVXF
iShares Micro-Cap ETFIWC
Dimensional - US Core Equity 2 ETFDFAC
Dimensional - US Core Equity 1 ETFDCOR
Dimensional - US Sustainability Core 1 ETFDFSUAI-generated and delayed market data for informational and educational purposes only. Not investment advice.